Dr. Charles Sawyers received a B.A. from Princeton University and an M.D. from Johns Hopkins University School of Medicine, followed by internal medicine residency at the University of California, San Francisco. He co-discovered the antiandrogen drug enzalutamide, which was approved in 2012 for the treatment of advanced prostate cancer. In 2009, he shared the Lasker-DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitors imatinib (Gleevec) and dasatinib (Sprycel) for patients with chronic myeloid leukemia. He has served as Chair of the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center since 2006.